Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 49, Issue 2, Pages 161-166Publisher
SPRINGER-VERLAG
DOI: 10.1007/s00280-001-0387-1
Keywords
rhIL-11; thrombocytopenia; Lewis lung carcinoma; tumor-bearing mice
Categories
Ask authors/readers for more resources
Purpose: Interleukin-11 (IL-11) is a stromal cell derived multifunctional cytokine, which plays important roles in the hematopoietic and nonhematopoietic systems. Recombinant human IL-11 (rhIL-11) is used in the treatment of chemotherapy-induced thrombocytopenia. We have investigated the effects of rhIL-11 on the antitumor activity of chemotherapeutic agents and on thrombocytopenia in myelosuppressed mice bearing tumor cells. Methods: We tested the effect of rhIL-11 on Lewis lung carcinoma (LLC) cell proliferation when used alone or in combination with three antitumor agents in vitro. Also, a newly developed chemotherapy-induced myelosuppressed mice model bearing LLC cells was used to study the effects of rhIL-11 on the antitumor activity and on thrombocytopenia. Results: On its own, rhIL-11 (1-100 ng/ml) did not stimulate cell proliferation, and did not alter the antitumor activities of carboplatin, mitomycin C, or etoposide in vitro. In mice implanted with LLC cells (1 x 10(4)), carboplatin (50 mg/kg/day for 2 consecutive days, i.p.) inhibited tumor growth and caused thrombocytopenia. Treatment with rhIL-11 (500 mug/kg/day, from the day following the last dosing with carboplatin for 14 days, s.c.) successfully prevented thrombocytopenia without affecting the antitumor activity of carboplatin. With rhIL-11 there was no obvious effect on the red blood cell count, white blood cell count, or body weight. Conclusion: These results support the assertion that rhIL-11 may be a significant therapeutic agent for thrombocytopenia following cancer chemotherapy, and that it need be associated with little fear of tumor proliferation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available